CPhI Worldwide 2015

Profile of a CEO: Piramal Chief shares M&A plans

By Fiona BARRY contact

- Last updated on GMT

Sharma plans to add to the company's acquisitions
Sharma plans to add to the company's acquisitions

Related tags: Pharmaceutical drug

Piramal chief executive Vivek Sharma won last week’s CPhI award for the pharma industry’s CEO of the year. Outsourcing-Pharma.com spoke to Sharma about his plans for the CDMO the day after the jury’s unanimous decision.

Sharma told us his roadmap for the company will increase Piramal’s capabilities, as well as the volume of orders.  

ADC expansion

The CEO plans more M&A in the near future, following the acquisition of Kentucky-based CDMO Coldstream for $30m​ in January this year.  The purchase added HPAPI (highly potent active pharmaceutical ingredient) capabilities to Piramal’s capabilities.

We don’t do HPAPI to the extent our customers area looking for […] and we were not able to provide our customers with fill-finish for ADCs [antibody drug conjugates]. Now we can do that with the Coldstream [facilities],​” said Sharma.

And while the company is “strong​” in injectables R&D, Sharma wants to increase its injectables manufacturing.  

We want to be number one for ADCs – with more integrated capabilities.​”

Piramal will firmly remain a CDMO, looking for acquisitions in areas “that complement what we do – such as API​,” said Sharma. “We are looking for significant growth in next 5 years – scale is important.​”

Judges’ opinion

The CPhI Pharma Awards jury member Gil Roth, also president of the Pharma & Biopharma Outsourcing Association told this publication the committee picked Sharma for his wide-ranging achievements.

"Vivek Sharma did an outstanding job of achieving long- and short-term goals at two of Piramal's major business units last year, which cover projects and services.

“He pulled off the difficult feat of reducing costs while investing for growth. In addition, he stood out for his work in acquiring Coldstream Laboratories and integrating the CMO's sterile injectables capabilities into array of Piramal Pharma Solutions' offerings.

Profile of a CEO

Runs Piramal​’s global business from Boston, Massachusetts.

Joined the company in 2011​, leading the Critical Care business. Focus on operational efficiency and geographic expansion. The inhalation anaesthetics biz is now the third largest globally.

Before Piramal​, Sharma was MD of Boston-based private equity firm THL Partners​. He has also worked in finance and operations at AMD​ & Motorola​.

Training​ A chartered accountant with an MBA from Thunderbird School of Management, Arizona.

Did you miss the awards? Read live coverage - and video - of the CPhI pharma awards on our sister site, in-Pharmatechnologist.com. ​ 

Related news

Show more

Related products

show more

Using SDTM, ADaM, and SEND

Using SDTM, ADaM, and SEND

Formedix | 09-Nov-2022 | Technical / White Paper

This article gives an overview of SDTM, ADaM, SEND and ARM, and discusses how these CDISC standards fit in with the wider clinical trial process, and how...



Indena | 25-Oct-2022 | Technical / White Paper

Indena is well known in the space of naturally derived molecules, with a know-how developed over its one hundred year history. At the same time, the company...

How to design an effective CRF

How to design an effective CRF

Formedix | 10-Oct-2022 | Technical / White Paper

CRFs and eCRFs are used for gathering patient data during clinical trials. They play a crucial role in helping to assess the safety and efficacy of clinical...

Related suppliers

Follow us


View more